Premium
Enhanced in vivo Magnetic Resonance Imaging of Tumors by PEGylated Iron‐Oxide–Gold Core–Shell Nanoparticles with Prolonged Blood Circulation Properties
Author(s) -
Kumagai Michiaki,
Sarma Tridib Kumar,
Cabral Horacio,
Kaida Sachiko,
Sekino Masaki,
Herlambang Nicholas,
Osada Kensuke,
Kano Mitsunobu R.,
Nishiyama Nobuhiro,
Kataoka Kazunori
Publication year - 2010
Publication title -
macromolecular rapid communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.348
H-Index - 154
eISSN - 1521-3927
pISSN - 1022-1336
DOI - 10.1002/marc.201000341
Subject(s) - in vivo , biodistribution , peg ratio , magnetic resonance imaging , ethylene glycol , pancreatic cancer , iron oxide nanoparticles , materials science , adenocarcinoma , pancreas , colloidal gold , spleen , nanoparticle , iron oxide , chemistry , cancer , nuclear magnetic resonance , medicine , nanotechnology , radiology , biochemistry , physics , microbiology and biotechnology , organic chemistry , finance , metallurgy , economics , biology
High‐density poly(ethylene glycol) (PEG)‐coated iron‐oxide–gold core–shell nanoparticles (AuIONs) were developed as T 2 ‐weighted magnetic resonance imaging (MRI) contrast agents for cancer imaging. The PEG‐coated iron‐oxide–gold core–shell nanoparticles (PEG‐AuIONs) were approximately 25 nm in diameter with a narrow distribution. Biodistribution experiments in mice bearing a subcutaneous colon cancer model prepared with C26 murine colon adenocarcinoma cells showed high accumulation of the PEG‐AuIONs within the tumor mass and low nonspecific accumulation in the liver and spleen, resulting in high specificity to solid tumors. T 2 ‐weighted MR images following intravenous injection of PEG‐AuIONs showed selective negative enhancement of tumor tissue in an orthotopic pancreatic cancer model prepared with MiaPaCa‐2 human pancreatic adenocarcinoma cells. These results indicate that PEG‐AuIONs are a promising MRI contrast agent for diagnosis of malignant tumors, including pancreatic cancer.